Docking and 3D-QSAR studies of diverse classes of human aromatase (CYP19) inhibitors

Roy, Partha; Roy, Kunal
October 2010
Journal of Molecular Modeling;Oct2010, Vol. 16 Issue 10, p1597
Academic Journal
omatase (cytochrome 19) inhibitors have emerged as promising candidates for treatment of breast cancer. In search of potent aromatase inhibitors, docking and three-dimensional quantitative structure - activity relationship (3D-QSAR) studies using molecular shape, spatial, electronic, structural and thermodynamic descriptors have been performed on a diverse set of compounds having human aromatase inhibitory activities. An attempt has also been made to include two-dimensional (2D) descriptors in the QSAR studies. The chemometric tools used for model development are genetic function approximation (GFA) and genetic partial least squares (G/PLS). The docking study shows that the important interacting amino acids in the active site cavity are Met374, Arg115, Ile133, Ala306, Thr310, Asp309, Val370 and Ser478. One or more hydrogen bond formation with Met374 is one of the essential requirements for the ligands for optimum aromatase inhibition. The binding is further stabilized by van der Waals interactions with a few non-polar amino acid residues in the active site. The developed QSAR models indicate the importance of different shape, Jurs parameters, structural parameters, topological branching index and E-state index for different fragments. The results obtained from the QSAR analysis are supported by our docking observations. There should be one or two hydrogen bond acceptor groups (like –NO, -CN) and optimal hydrophobicity for ideal aromatase inhibitors. A GFA model with spline option obtained using 3D descriptors was found to be the best model based on internal validation (Q = 0.668) while the best (externally) predictive model was a GFA model with spline option using combined set (2D and 3D) descriptors (R = 0.687). Based on r criterion, the best model was a G/PLS model (using 3D descriptors) with spline option (r = 0.606). [Figure not available: see fulltext.]


Related Articles

  • Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Ghosh, Debashis; Griswold, Jennifer; Erman, Mary; Pangborn, Walter // Nature;1/8/2009, Vol. 457 Issue 7226, p219 

    Aromatase cytochrome P450 is the only enzyme in vertebrates known to catalyse the biosynthesis of all oestrogens from androgens. Aromatase inhibitors therefore constitute a frontline therapy for oestrogen-dependent breast cancer. In a three-step process, each step requiring 1 mol of O2, 1 mol of...

  • Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study. Mustacchi, G.; Mansutti, M.; Sacco, C.; Barni, S.; Farris, A.; Cazzaniga, M.; Cozzi, M.; Dellach, C. // Annals of Oncology;Apr2009, Vol. 20 Issue 4, p655 

    Background: The steroidal aromatase inhibitor exemestane has demonstrated efficacy for the treatment of breast cancer in the metastatic and adjuvant settings. Smaller trials have also reported efficacy in the neo-adjuvant setting.

  • New steroidal aromatase inhibitors: Suppression of estrogen-dependent breast cancer cell proliferation and induction of cell death. Cepa, Margarida; Correia-da-Silva, Georgina; Tavares da Silva, Elisi´rio J.; Roleira, Fernanda M. F.; Borges, Margarida; Teixeira, Natércia A. // BMC Cell Biology;2008, Vol. 9, Special section p1 

    Background: Aromatase, the cytochrome P-450 enzyme (CYP19) responsible for estrogen biosynthesis, is an important target for the treatment of estrogen-dependent breast cancer. In fact, the use of synthetic aromatase inhibitors (AI), which induce suppression of estrogen synthesis, has shown to be...

  • Combined Structure-Based Pharmacophore and 3D-QSAR Studies on Phenylalanine Series Compounds as TPH1 Inhibitors. Ouyang, Liang; He, Gu; Huang, Wei; Song, Xiangrong; Wu, Fengbo; Xiang, Mingli // International Journal of Molecular Sciences;May2012, Vol. 13 Issue 5, p5348 

    Tryptophan hydroxylase-1 (TPH1) is a key enzyme in the synthesis of serotonin. As a neurotransmitter, serotonin plays important physiological roles both peripherally and centrally. In this study, a combination of ligand-based and structure-based methods is used to clarify the essential...

  • Anastrozole rivals tamoxifen as first-line choice for advanced breast cancer.  // Formulary;Nov99, Vol. 34 Issue 11, p904 

    Reports on the results of a comparative study on the effectiveness of the aromatase inhibitor anastrozole as a first-line treatment of advanced postmenopausal breast cancer. Subject patients; Treatment regimen; Effect of estrogen receptor in the efficacy of anastrozole; Side effect profile.

  • Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer. Miller, W.R.; Stuart, M.; Sahmoud, T.; Dixon, J.M. // British Journal of Cancer;10/21/2002, Vol. 87 Issue 9, p950 

    The effect of anastrozole on peripheral and turnout aromatase activity and oestrogen levels in postmenopausal patients with oestrogen receptor-rich breast tumours was investigated. Twenty-six patients were randomly allocated to treatment with anastrozole 1 mg (n = 13) or 10 mg (n = 13), once...

  • Breast cancer guidelines suggest alternative to standard therapy. Lewis, Jillene // Drug Topics;8/18/2003, Vol. 147 Issue 16, p22 

    Reports on the potential of aromatase inhibitor anastrozole as an alternative treatment for breast cancer. Analysis of the results of clinical trials of anastrozole; Recurrence rate of cancer in women studied.

  • ESMO 2009: findings confirm adjuvant use of aromatase inhibitors in early breast cancer.  // PharmaWatch: Monthly Review;Nov2009, Vol. 8 Issue 11, p15 

    The article focuses on the findings regarding the use of aromatase inhibitors for treating patients with early breast cancer. It notes the positive data from the TEAM study confirmed that adjuvant Aromasin is superior to tamoxifen in early-stage breast cancer. However, despite the positive...

  • Exemestane.  // Reactions Weekly;9/18/2010, Issue 1319, p24 

    The article describes the case of a 55-year-old woman who was suffering intraepithelial microcysts radiating from the limbus of both eyes after receiving exemestane 25 milligrams (mg) per day for breast cancer.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics